artus gains worldwide PCR (Polymerase Chain Reaction) licence:
This article was originally published in Clinica
Executive Summary
German biotechnology company artus has been granted a licence for the worldwide commercial use of the Polymerase Chain Reaction (PCR) technology by Hoffmann-La Roche. Hamburg-based artus, which specialises in pathogen diagnosis through genetic procedures, will now be able to manufacture and market diagnostic products based on PCR, for the detection of herpes viruses and other infectious diseases. In addition to PCR detection procedures using gels, artus is intensifying research into real-time systems that enable rapid, quantitative and reliable pathogen detection.